RENIN

RENIN Overview

English NameReninApproved Drugs4
Drugs in Clinical Trials3Target SynonymREN,Renin,Angiotensinogenase,Angiotensin-Forming Enzyme,Renin Precursor, Renal,HNFJ2,EC:3.4.23.15,EC 3.4.23.15,EC 3.4.23
Highest Development StageApproved
English NameRenin
Target SynonymREN,Renin,Angiotensinogenase,Angiotensin-Forming Enzyme,Renin Precursor, Renal,HNFJ2,EC:3.4.23.15,EC 3.4.23.15,EC 3.4.23
Approved Drugs4
Drugs in Clinical Trials3
Highest Development StageApproved

RENIN Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (1)Mouse (1)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
REN-H5221
Human
HEK293
Human RENIN Protein, His Tag
REN-M5222
Mouse
HEK293
Mouse RENIN Protein, His Tag
Total: 2
  • 1

RENIN Background

Renin is also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body's renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2. The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3' UTR. An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.

RENIN Synonyms

REN,FLJ10761,Renin,angiotensinogenase

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MT-2765MT-2765Phase 3 ClinicalMitsubishi Tanabe Pharma CorpHypertension
Details
SP-20104 (Sarfez Pharmaceuticals)SP-20104Phase 2 Clinical1 A Pharma GmbhGlomerulosclerosis, Focal Segmental
Details
Imarikiren hydrochlorideTAK-272; SCO-272Phase 2 ClinicalTakeda Pharmaceutical Co LtdDiabetic Nephropathies; Hepatic Insufficiency; Hypertension; Renal Insufficiency
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Aliskiren Hemifumarate/Amlodipine Besilate/HydrochlorothiazideApprovedNovartis Pharma AgRasitrio, AmturnideUnited StatesHypertensionnull2010-12-21Essential Hypertension; Hypertension
Details
Sitokiren MalateMT-2765; MT2765; I-001; SPH-3127; I001-A; I001-BApprovedMitsubishi Tanabe Pharma, Shanghai Pharmaceuticals Holding Co Ltd信妥安Mainland ChinaEssential HypertensionShanghai Sine Pharmaceutical Laboratories Co Ltd2025-12-03Colitis, Ulcerative; Diabetic Nephropathies; Essential Hypertension; Hypertension; Kidney Diseases; Psoriasis
Details
Aliskiren HemifumarateCGP-60536; SPP-100; SPP-100B; SPP-100A; CGP-60536BApprovedNovartis Pharma AgSprimeo, Enviage, Tekturna, Riprazo, 锐思力, RasilezUnited StatesHypertensionNoden Pharma Dac2007-03-05Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Essential Hypertension; Glomerulonephritis, IGA; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Myocardial Ischemia; Overweight
Details
AliskirenApprovedMainland ChinaEssential HypertensionNovartis Pharma Ag2010-03-26Essential Hypertension
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8